FDA Approves Combination Treatment for Metastatic Prostate Cancer
The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a... Read More
The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a... Read More
The complexity of treating and managing prostate cancer during every stage of the disease, and the involvement of the number... Read More
The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment... Read More
More than 12 percent of men with prostate cancer tested positive for hereditary mutations of cancer-causing genes, according to study... Read More
Janssen Biotech announced that the Food and Drug Administration has approved Zytiga (abiraterone acetate) in combination with prednisone for high-risk... Read More
Men who consume whole milk following their prostate cancer diagnosis may increase their risk for disease recurrence, especially overweight or... Read More
Jevtana (cabazitaxel) was granted approval by the Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant... Read More
When it comes to active surveillance and prostate-specific antigen (PSA) screening for localized prostate cancer, the paradigm has been shifting... Read More
What stands in the way of patient-physician communications and how can we get around these barriers? Read more.
Previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age... Read More